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Resumo
A análise de sobrevivência é uma classe de métodos estatísticos usados para estudar o tempo até a ocorrência de um evento. Os
métodos usuais assumem que todos os indivíduos sob estudo são sujeitos ao evento de interesse. Entretanto, há situações em que
este pressuposto não é real. Por exemplo, em uma pesquisa clínica, uma proporção de pacientes pode responder favoravelmente
ao tratamento sob investigação e consequentemente não morrer devido à doença. Modelos baseados em distribuições defectivas
são adequados para analisar dados com estas características. Neste artigo, apresentamos inferências Bayesianas e de máxima
verossimilhança para o modelo de fração de cura baseado na distribuição defectiva de Gompertz, incluindo covariáveis. Um
exemplo de aplicação à sobrevida livre de doença de mulheres tratadas para câncer cervical é usado para ilustrar a metodologia.
Na análise Bayesiana, distribuições a posteriori dos parâmetros foram estimadas por métodos Monte Carlo em cadeias de Markov
(MCMC). Códigos R, SAS e OpenBUGS são apresentados em um apêndice no final do artigo aos leitores que desejarem usar o
método para conduzir suas próprias análises.
Palavras-chave: Estimação de máxima verossimilhança, Inferência Bayesiana, Distribuições defectivas, Análise de sobrevida,
Distribuição Gompertz modificada.
Abstract
Survival analysis is a class of statistical methods to study the time until the occurrence of a specified event. The usual methods
assume that all individuals under study are subjects to the event the interest. However, there are situations where this case
is unrealistic. For example, in a clinical research, a proportion of patients could respond favourably to the treatment under
investigation and consequently they would not die from the disease. Models based on defective distributions are a suitable way to
analyse data with these characteristics. In this paper, we present Bayesian and maximum likelihood inference for the defective
Gompertz cure rate model in presence of covariates. An example with application to disease-free survival of women treated for
cervical carcinoma is used to illustrate the proposed methodology. In the Bayesian analysis, posterior distributions of parameters
are estimated using the Markov chain Monte Carlo (MCMC) method. R, SAS and OpenBUGS codes are provided in an appendix
at the end of the paper so that reader can carry out their own analysis.
Keywords: Maximum likelihood estimation, Bayesian inference, Defective distributions, Survival analysis, Modified Gompertz
distribution.
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1 Introduction
Statistical lifetime methods are widely used in studies considering the analysis of data sets in the health area, when the variable of
interest is related to the time until the occurrence of an event (Klein and Moeschberger, 2005). This event can be, for example,
the first recurrence of a disease after treatment, death due to a specific cause or discharge after a hospital admission. While
many methods of survival analysis are readily available in statistical computer packages, most of these techniques assume that all
individuals are susceptible to the occurrence of the event of interest. However, this assumption can be unrealistic in some specific
situations, when there is a subpopulation of individuals that is immune or not susceptible to the occurrence of the event of interest.
As an example, in a clinical research, a proportion of patients can respond favourably to the treatment under investigation and be
regarded as "cured". A number of statistical tools have been developed to handle such data, especially the cure fraction models
(Lambert et al., 2007).
These models include as a special case the mixture model (Farewell, 1982), that explicitly includes a parameter accounting for
the cure rate. The mixture model assumes that the probability of the time-to-event to be greater than a specified time t is given by
the survival function
S(t) = P (T > t) = p+ (1− p)S0(t),
where p is a parameter which represents the proportion of "cured patients", regarding the event of interest (0 < p < 1), and S0(t)
is the baseline survival function for the susceptible individuals (Maller and Zhou, 1996). Common choices for S0(t) are the
Gompertz, exponential and Weibull distributions. The probability density function for the lifetime T is given by
f(t) =
dF (t)
dt
= (1− p) f0(t),
where F (t) = 1− S(t) and f0(t) is the baseline probability density function for the susceptible individuals.
Models based on defective distributions are alternatives to the mixture model. A defective distribution is defined as a
distribution that is not normalized to one for some values of their parameters, and it can be useful to fit data including both immune
and susceptible individuals without explicitly including the parameter p. The use of defective distribution in survival analysis have
been considered by a number of authors, including Balka et al. (2011), Cancho and Bolfarine (2001) and Rocha et al. (2014).
In this paper we propose Bayesian and frequentist approaches to a model based on the modified Gompertz distribution,
considering survival data in presence of a cure fraction. More recently a number of new families of defective distributions have
been proposed in the literature, such as those based on the Kumaraswamy Rocha et al. (2015) and the Marshall–Olkin families
Rocha et al. (2017). However, in the present study, the modified Gompertz distribution was preferred because of its computational
simplicity and the ease of interpretation of their parameters. Our methodology is motivated by a real data set that arises from the
cervical carcinoma study by Brenna et al. (2004) and it extends the model described by Rocha et al. (2014) to the situation in
which covariates are present. The computational codes used in this article are provided in the Appendix.
2 Methods
2.1 The modified Gompertz model
The modified Gompertz hazard function was first used by Cantor and Shuster (1992) for estimation of cure rates from paediatric
clinical trials and after extended by Gieser et al. (1998) to include covariate effects. This model assumes a survival function given
by
S(t) = exp
{
−α
β
[1− exp (−βt)]
}
,
where t > 0, α > 0 is a shape parameter, β > 0 is a scale parameter, and the corresponding cure rate η is given by
lim
t−→∞S(t) = exp
(
−α
β
)
= η,
where 0 < η < 1. In addition, the corresponding probability density function is given by
f(t) = α exp (−βt) exp
{
−α
β
[1− exp (−βt)]
}
and the hazard function is given by
h (t) =
f(t)
S(t)
= α exp (−βt) .
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2.2 Maximum likelihood estimation
Considering a random sample (ti,δi) of size n, i = 1,...,n, the contribution of the ith subject for the likelihood function is given by
Li = [f(ti)]
δi [S(ti)]
1−δi = S(ti) [h(ti)]
δi ,
where δi is a censoring indicator variable, that is, δi = 1 for an observed lifetime and δi = 0 for a censored lifetime.
Assuming the modified Gompertz model, the likelihood function for θ = (α,β) is given by
L(θ) =
n∏
i=1
αδi exp
{
−α
β
[1− exp (−βti)]− βδiti
}
and the corresponding log-likelihood function is
l(θ) = (lnα)
n∑
i=1
δi − α
β
n∑
i=1
[1− exp (−βti)]− β
n∑
i=1
δiti.
By deriving the log-likelihood function with respect to α and β, we have the following equations:
∂l(θ)
∂α
=
1
α
n∑
i=1
δi − 1
β
n∑
i=1
(
1− e−βti)
and
∂l(θ)
∂β
=
α
[
n∑
i=1
(
1− e−βti)− β n∑
i=1
e−βtiti
]
β2
−
n∑
i=1
δiti.
Setting these expressions equal to zero, we get the corresponding score equations whose numerical solution leads to the maximum
likelihood estimators (MLE). Although we cannot obtain explicit expressions for the MLEs for the parameters α and β, they can
be estimated numerically using iterative algorithms such as the Newton-Raphson method and its variants (Rocha et al., 2014). R
(R Development Core Team, 2009) and SAS (Littell et al., 2006) codes for implementing these procedures are presented in the
Appendix.
The asymptotic variances of MLEs are given by the elements of the inverse of the Fisher’s information matrix I(α,β). The
second partial derivatives of the maximum likelihood function are given as follows:
∂2
∂α2
l(θ) = − 1
α2
n∑
i=1
δi,
∂2
∂β2
l(θ) =
α
β2
[
n∑
i=1
e−βti (2 + βti)− 2
β
+
n∑
i=1
tie
−βti (1 + βti)
]
and
∂2
∂αβ
l(θ) = −
n∑
i=1
e−βti (1 + βti)− 1
β2
.
Therefore, the expected Fisher’s information matrix is given by
I(α,β) =
 −E [ ∂2∂α2 l(θ)] −E [ ∂2∂αβ l(θ)]
−E
[
∂2
∂αβ l(θ)
]
−E
[
∂2
∂β2 l(θ)
]  .
In practical applications we could use the observed Fisher’s information matrix given the difficulties to get the expected matrix
in the determination of the asymptotical normality of the MLEs used to construct confidence intervals and hypotheses tests for
the parameters of the model. Wald-type 95% confidence intervals for the parameters can be thus obtained from the respective
estimates of the standard errors.
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2.3 Model with covariates
In order to include covariates, the parameter α in the likelihood function L(θ) can be replaced by a function α(xi) such as
lnα(xi) = xiα
∗,
where xi = (1,x1i,x2i,...,xpi) is a vector containing observations on p independent variables and α∗ = (α0,α1,...,αp) is a vector
of unknown parameters. Analogously, the parameter β in L(θ) can be replaced by an function β(wi) such as
lnβ(wi) = wiβ
∗,
where wi = (1,w1i,w2i,...,wqi) is a vector which may or may not be equal to xi and β∗ = (β0,β1,...,βq) is a vector of unknown
parameters.
Comparisons between different model formulations can be based on the Akaike’s information criterion (AIC) (Akaike, 1973).
The model with the lowest AIC value suggest a better fit to the data.
2.4 Bayesian analysis
The Bayesian method considers that prior distributions of the parameters of the model are used to derive their corresponding
posterior densities (Gelman et al., 2013). According to the Bayes theorem, we can write the joint posterior density by combining
the joint prior distribution with the likelihood function for α and β. In this case, Markov chain Monte Carlo (MCMC) is a useful
method to sample from posterior probability distributions by means of simulation.
For a Bayesian analysis of the model without covariates, we assume inverse gamma (IG) prior distributions for the parameters
α and β, considering that these parameters are real and positive numbers. Thus,
α ∼ IG(a1,b1)
and
β ∼ IG(a2,b2),
where a1, b1, a2 and b2 are known hyperparameters. The mean and variance of a random variable following the inverse gamma
distribution with parameters a and b are given by
b
a− 1 and
b2
(a− 1)2 (a− 2) ,
respectively. Therefore, an improper prior distribution is considered if a ≤ 2. An improper prior distribution is not a true
probability distribution in that it does not integrate to 1. In Bayesian inference, an improper prior distribution is acceptable, in the
sense that the corresponding posterior distribution is proper.
In the case of the model with covariates, consider the following prior distributions for the parameters:
αj ∼ N(cj ,dj), j = 0,1,...,p,
and
βk ∼ N(ek,fk), k = 0,1,...,q,
where N(c,d) denotes a normal distribution with mean c and variance d, and cj , dj , ek and fk (j = 0,1,...,p and k = 0,1,...,q) are
known hyperparameters.
Posterior summaries of interest will be obtained in the examples section from simulated samples for the joint posterior
distribution using standard MCMC procedures, as the Gibbs sampling. We will generate 1,005,000 samples for each parameter of
interest. The 5,000 first simulated samples will be discarded as a burn-in period, which is usually used to minimize the effect
of the initial values. The posterior summaries of interest will be based on 10,000 samples, taking every 100th sample to have
approximately uncorrelated values. We assume prior independence between all model parameters. The Bayes estimates of the
parameters will be obtained as the mean of samples drawn from the joint posterior distribution. In addition, 95% credible intervals
for the parameters are given by the 0.025th and 0.975th percentiles of the respective posterior distributions. Convergence of the
MCMC algorithm will be monitored by usual time series plots for the simulated samples and also using some existing Bayesian
convergence methods.
Posterior summaries of interest will be obtained using the OpenBUGS software (Lunn et al., 2000), that only requires the
specification of the distribution for the data and the prior distributions for the parameters. See Appendix for details about the
OpenBUGS codes used.
The Deviance Information Criterion (DIC) will be used to compare the fit of different model formulations (Spiegelhalter et al.,
2014). Smaller values correspond to models that provide better fit to the data.
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Table 1: Results from the simulation study: coverage probabilities of the Wald-type confidence intervals for the parameters α, β
and η, biases and mean squared errors (MSE).
Nominal
values
n
Coverage
probability
Bias MSE
α 0.9381 0.0201 0.0223
25 β 0.9591 0.0123 0.0255
η 0.7800 0.0045 0.0134
α 0.9485 0.0090 0.0095
50 β 0.9541 0.0022 0.0088
η 0.8756 -0.0018 0.0064
α 0.9493 0.0046 0.0059
75 β 0.9545 -0.0007 0.0046
α = 0.4 η 0.9158 -0.0034 0.0039
β = 0.2 α 0.9478 0.0045 0.0043
100 β 0.9476 0.0007 0.0031
η 0.9248 -0.0022 0.0028
α 0.9480 0.0013 0.0027
150 β 0.9496 -0.0004 0.0017
η 0.9344 -0.0016 0.0017
α 0.9482 0.0022 0.0019
200 β 0.9538 0.00004 0.0012
η 0.9426 -0.0014 0.0012
α 0.9158 0.0928 1.3430
25 β 0.9638 0.1241 0.4927
η 0.7311 -0.1127 0.0978
α 0.9300 0.0245 0.0202
50 β 0.9675 0.0886 0.2825
η 0.9036 -0.0469 0.0338
α 0.9408 0.0192 0.0125
75 β 0.9582 0.0585 0.1344
α = 0.3 η 0.9316 -0.0243 0.016
β = 0.7 α 0.9434 0.0095 0.0078
100 β 0.9543 0.0284 0.0742
η 0.9404 -0.0146 0.0087
α 0.9428 0.0075 0.0049
150 β 0.9570 0.0225 0.0393
η 0.9508 -0.0048 0.0034
α 0.9424 0.0069 0.0037
200 β 0.9510 0.0185 0.0254
η 0.9520 -0.0027 0.0021
2.5 A simulation method for a random variable with a modified Gompertz distribution
The algorithm used to simulate a sample of size n from the modified Gompertz distribution with right-censored data follows the
steps:
Step 1. Fix values of α and β.
Step 2. Generate n random samples from
Mi ∼ Bernoulli(0,1− η),
where η is the corresponding cure rate given by
η = exp
(
−α
β
)
.
Step 3. Consider
t′i =
{ ∞ ifMi = 0
F−1Y (Ui) ifMi = 1
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Table 2: Maximum likelihood estimates
Parameter Estimate Std. error Wald-type 95% CI
α 0.04178 0.00747 (0.0271 , 0.0564)
β 0.03995 0.00795 (0.0243 , 0.0555)
η 0.35147 0.05440 (0.2446 , 0.4584)
where
F−1Y (Ui) = −
1
β
ln
[
1 +
β
α
ln (1− Ui)
]
and
Ui ∼ Uniform(0,1− η).
Step 4. Generate n random samples from
u′i ∼ Uniform(0,max(t′i)),
considering only the finite t′i.
Step 5. Calculate ti = min(t′i,u
′
i).
Step 6. Pairs of values (t1,δ1), (t2,δ2),...,(tn,δn) are thus obtained, where δi = 1 if ti < u′i and δi = 0 if ti ≥ u′i, i = 1,...,n.
This algorithm is similar to that presented by Rocha et al. (2017). An R function for generating random samples based on
these steps is presented in the Appendix.
3 Results
3.1 Simulation study
A brief simulation study of the performance of the maximum likelihood method of estimation was carried on based on simulated
samples of sizes n = 25, 50, 75, 100, 150 and 200. Each sample was replicated 5000 times. The variance of the cure rate η was
estimated using the delta method. The results from the simulation study are presented in Table 1, considering a nominal confidence
coefficient of 95 per cent and two sets of arbitrary values for the parameters, given by (α,β) = (0.4,0.2) and (α,β) = (0.3,0.7).
The results in Table 1 show that the coverage probability of the Wald-type confidence intervals for the parameters α and
β is quite close to the nominal confidence level of 95%. Furthermore, the coverage probability of the confidence intervals for
η approaches 95% as the sample size is increased. In all simulations, the biases and the mean squared errors (MSE) always
approached zero as the sample size increased.
3.2 An application to real data
Let us consider the data from a study that included a total of 148 women diagnosed and treated for invasive cervical carcinoma
between 1992 and 2002 (Brenna et al., 2004). For the purposes of the present study, it was considered a subsample of 118 women
who received the standard treatment recommended by the International Federation of Gynecology and Obstetrics (FIGO). Let
us define the disease-free survival (DFS) as the time in complete months from the date of surgery to the first event of disease
recurrence. Nearly 48% of the data are censored observations.
Figure 1 is a contour plot of the log of the likelihood function for these data, considering the parametric model based
on the modified Gompertz distribution. The plot indicates that the maximum of the log-likelihood function is at (α,β) =
(0.04178, 0.03995), as showed in the Table 2. Table 2 shows the maximum likelihood estimates of α, β and the cure rate η, as
well as the estimates of their standard errors and confidence intervals. Figure 2 shows plots of the Kaplan-Meier estimates for
the survival function and the predicted values obtained from the parametric model against times (months). From Figure 2, it is
possible to note that the predicted values obtained from the model based on the modified Gompertz distribution are closest to the
empirical values, suggesting that this model is well fitted for the data.
The cure rate is estimated by
η̂ = exp
(
− α̂
β̂
)
= 0.35147,
and the respective standard error was obtained by the Delta method as a first-order approximation of a Taylor-series expansion
(Table 2).
3 Results
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recurrence. Nearly 48% of the data are censored observations.
Figure 1 is a contour plot of the log of the likelihood function for these data, considering the parametric model based
on the modified Gompertz distribution. The plot indicates that the maximum of the log-likelihood function is at (α,β) =
(0.04178, 0.03995), as showed in the Table 2. Table 2 shows the maximum likelihood estimates of α, β and the cure rate η, as
well as the estimates of their standard errors and confidence intervals. Figure 2 shows plots of the Kaplan-Meier estimates for
the survival function and the predicted values obtained from the parametric model against times (months). From Figure 2, it is
possible to note that the predicted values obtained from the model based on the modified Gompertz distribution are closest to the
empirical values, suggesting that this model is well fitted for the data.
The cure rate is estimated by
η̂ = exp
(
− α̂
β̂
)
= 0.35147,
and the respective standard error was obtained by the Delta method as a first-order approximation of a Taylor-series expansion
(Table 2).
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Figure 1: Contour plot of the log-likelihood function, considering the data from the cervical carcinoma study. The maximizing
point is (α,β) = (0.04178, 0.03995).
Table 3: Bayesian estimates
Parameter Estimate 95% credible intervals
α 0.04134 (0.0282 , 0.0574)
β 0.03928 (0.0244 , 0.0557)
η 0.3474 (0.2380 , 0.4554)
Table 3 shows the Bayesian estimates of α, β and the cure rate η, with their respective 95% credible intervals. In this
analysis, it was considered the hyperparameters a1 = b1 = a2 = b2 = 0.001 in order to obtain noninformative priors, that is,
α ∼ IG(0.001,0.001) and β ∼ IG(0.001,0.001). We can note that the Bayesian estimates for the parameters are relatively close
to those obtained by the maximum likelihood method (Table 2).
3.3 Model with covariates
In order to illustrate an application of the regression model based on the modified Gompertz distribution, in this analysis we
consider the following variables:
• Age of the patients at start of follow-up (x1), classified as less than 50 years (x1 = 0) versus greater or equal to 50 years
(x1 = 1).
• Clinical stage of the disease at the start of treatment, classified as I, II, or III. This variable is represented in the regression
model by using two dummy variables (x2 and x3), where x2 = 0 and x3 = 0 if stage I, x2 = 1 and x3 = 0 if stage II, and
x2 = 0 and x3 = 1 if stage III.
Thus, the regression model for the data considers that
lnα(x) = α0 + α1x1 + α2x2 + α3x3 + α12x1x2 + α13x1x3
and
lnβ(x) = β0 + β1x1 + β2x2 + β3x3 + β12x1x2 + β13x1x3,
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Figure 2: Plots of the disease-free survival functions estimated from the Kaplan-Meier method and the parametric model based on
the modified Gompertz distribution. Censored observations are marked by ticks on the survival curve.
where α12, α13, β12 and β13 are interaction terms. Let us consider the following model formulations:
• Model 1: Model 1 considers only the effect of age (x1). In this case, α2, α3, α12, α13, β2, β3, β12 and β13 are considered
equal to zero.
• Model 2: Model 2 considers only the effect of the stage of the disease (dummy variables x2 and x3). In this case, α1, β1
and the interaction terms α12, α13, β12 and β13, are considered equal to zero.
• Model 3: Model 3 considers the effects of age (x1) and the stage of the disease (x2 and x3) but it does not includes the
interaction terms α12, α13, β12 and β13.
• Model 4: Model 4 considers the effects of age (x1) and the stage of the disease (x2 and x3) and it includes the interaction
terms α12, α13, β12 and β13.
For all regression coefficients, we assumed normal prior distributions with mean 0 and large variance. Both Bayesian and
maximum likelihood estimates are shown in Table 4. The fit of the Models 1 and 2 also considered the estimation of the cure
fraction (η) for each level of the respective independent variable. In the frequentist estimation, standard errors for the cure fraction
were calculated using the Delta method. As an illustration, Figure 3 shows the survival curves estimated by the Kaplan-Meier
method and by the Model 2 using the maximum likelihood approach.
Table 4 shows that the maximum likelihood and the Bayesian estimates are fairly close to each other. Model 1 suggests that
the age do not have a significant effect on the disease-free survival, since the confidence and credible intervals for the parameters
α1 and β1 include the value 0. Model 2 suggests a significant effect of the stage of the disease on the disease-free survival, given
that the confidence and credible intervals for the shape parameters α2 and α3 do not include the zero value (Figure 3).
Although the Model 1 does not evidences a significant effect of the age on the disease-free survival, Model 4 suggest that the
interaction between age and the clinical stages is important to understand the role of the age on the time to progression of the
disease. The confidence and credible intervals for the interaction terms β12 and β13 do not include the zero value, suggesting a
significant effect of interaction. In fact, the survival curves showed in the Figure 4 help us to understand this effect. The parametric
curves in Figure 4 were obtained based on the Model 4, and shown that the age has a strong effect on the disease-free survival of
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where α12, α13, β12 and β13 are interaction terms. Let us consider the following model formulations:
• Model 1: Model 1 considers only the effect of age (x1). In this case, α2, α3, α12, α13, β2, β3, β12 and β13 are considered
equal to zero.
• Model 2: Model 2 considers only the effect of the stage of the disease (dummy variables x2 and x3). In this case, α1, β1
and the interaction terms α12, α13, β12 and β13, are considered equal to zero.
• Model 3: Model 3 considers the effects of age (x1) and the stage of the disease (x2 and x3) but it does not includes the
interaction terms α12, α13, β12 and β13.
• Model 4: Model 4 considers the effects of age (x1) and the stage of the disease (x2 and x3) and it includes the interaction
terms α12, α13, β12 and β13.
For all regression coefficients, we assumed normal prior distributions with mean 0 and large variance. Both Bayesian and
maximum likelihood estimates are shown in Table 4. The fit of the Models 1 and 2 also considered the estimation of the cure
fraction (η) for each level of the respective independent variable. In the frequentist estimation, standard errors for the cure fraction
were calculated using the Delta method. As an illustration, Figure 3 shows the survival curves estimated by the Kaplan-Meier
method and by the Model 2 using the maximum likelihood approach.
Table 4 shows that the maximum likelihood and the Bayesian estimates are fairly close to each other. Model 1 suggests that
the age do not have a significant effect on the disease-free survival, since the confidence and credible intervals for the parameters
α1 and β1 include the value 0. Model 2 suggests a significant effect of the stage of the disease on the disease-free survival, given
that the confidence and credible intervals for the shape parameters α2 and α3 do not include the zero value (Figure 3).
Although the Model 1 does not evidences a significant effect of the age on the disease-free survival, Model 4 suggest that the
interaction between age and the clinical stages is important to understand the role of the age on the time to progression of the
disease. The confidence and credible intervals for the interaction terms β12 and β13 do not include the zero value, suggesting a
significant effect of interaction. In fact, the survival curves showed in the Figure 4 help us to understand this effect. The parametric
curves in Figure 4 were obtained based on the Model 4, and shown that the age has a strong effect on the disease-free survival of
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Figure 1: Contour plot of the log-likelihood function, considering the data from the cervical carcinoma study. The maximizing
point is (α,β) = (0.04178, 0.03995).
Table 3: Bayesian estimates
Parameter Estimate 95% credible intervals
α 0.04134 (0.0282 , 0.0574)
β 0.03928 (0.0244 , 0.0557)
η 0.3474 (0.2380 , 0.4554)
Table 3 shows the Bayesian estimates of α, β and the cure rate η, with their respective 95% credible intervals. In this
analysis, it was considered the hyperparameters a1 = b1 = a2 = b2 = 0.001 in order to obtain noninformative priors, that is,
α ∼ IG(0.001,0.001) and β ∼ IG(0.001,0.001). We can note that the Bayesian estimates for the parameters are relatively close
to those obtained by the maximum likelihood method (Table 2).
3.3 Model with covariates
In order to illustrate an application of the regression model based on the modified Gompertz distribution, in this analysis we
consider the following variables:
• Age of the patients at start of follow-up (x1), classified as less than 50 years (x1 = 0) versus greater or equal to 50 years
(x1 = 1).
• Clinical stage of the disease at the start of treatment, classified as I, II, or III. This variable is represented in the regression
model by using two dummy variables (x2 and x3), where x2 = 0 and x3 = 0 if stage I, x2 = 1 and x3 = 0 if stage II, and
x2 = 0 and x3 = 1 if stage III.
Thus, the regression model for the data considers that
lnα(x) = α0 + α1x1 + α2x2 + α3x3 + α12x1x2 + α13x1x3
and
lnβ(x) = β0 + β1x1 + β2x2 + β3x3 + β12x1x2 + β13x1x3,
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Table 4: Maximum likelihood and Bayesian estimates, model with covariates
Maximum likelihood estimates Bayesian estimates
Parameter Estimate Std. error Wald-type 95% CI AIC Estimate 95% credible interval DIC
Model 1 592.9 593.3
α0 (intercept) -3.041 0.2493 (-3.532 , -2.551) -3.091 (-3.629 , -2.585)
α1 (age ≥ 50 vs. < 50) -0.258 0.3578 (-0.961 , 0.445) -0.285 (-1.032 , 0.455)
β0 (intercept) -3.020 0.2637 (-3.539 , -2.501) -3.084 (-3.711 , -2.580)
β1 (age ≥ 50 vs. < 50) -0.386 0.4036 (-1.178 , 0.407) -0.461 (-1.524 , 0.424)
η1 (cure fraction, age ≥ 50) 0.376 0.0756 (0.227 , 0.524) 0.371 (0.214 , 0.523)
η2 (cure fraction, age < 50) 0.329 0.0794 (0.173 , 0.485) 0.311 (0.121 , 0.471)
Model 2 565.2 563.4
α0 (intercept) -4.825 0.5266 (-5.859 , -3.790) -4.850 (-5.746 , -3.972)
α2 (stage II vs. I) 1.814 0.6071 (0.621 , 3.007) 1.734 (0.636 , 2.820)
α3 (stage III vs. I) 2.325 0.5789 (1.187 , 3.462) 2.281 (1.258 , 3.285)
β0 (intercept) -4.093 0.8831 (-5.828 , -2.358) -4.269 (-6.409 , -3.070)
β2 (stage II vs. I) 0.948 0.9590 (-0.936 , 2.832) 0.902 (-0.939 , 3.153)
β3 (stage III vs. I) 0.803 0.9348 (-1.034 , 2.639) 0.839 (-0.665 , 3.085)
η1 (cure fraction, stage I) 0.618 0.1726 (0.278 , 0.957) 0.560 (0.043 , 0.814)
η2 (cure fraction, stage II) 0.319 0.1026 (0.117 , 0.520) 0.291 (0.039 , 0.506)
η3 (cure fraction, stage III) 0.110 0.0554 (0.001 , 0.219) 0.106 (0.014, 0.231)
Model 3 563.7 560.8
α0 (intercept) -5.490 0.369 (-6.226 , -4.753) -5.486 (-6.244 , -4.828)
α1 (age ≥ 50 vs. < 50) 0.297 0.340 (-0.396 , 0.991) 0.260 (-0.433 , 0.898)
α2 (stage II vs. I) 2.529 0.452 (1.638 , 3.421) 2.387 (1.571 , 3.255)
α3 (stage III vs. I) 2.602 0.415 (1.778 , 3.424) 2.527 (1.765 , 3.366)
β0 (intercept) -12.674 2.443 (-15.654 , -9.795) -13.020 (-17.140 , -9.101)
β1 (age ≥ 50 vs. < 50) 2.012 0.994 (-0.168 , 4.192) 2.853 (0.575 , 6.468)
β2 (stage II vs. I) 8.713 2.680 (5.166 , 12.359) 8.071 (4.553 , 11.790)
β3 (stage III vs. I) 7.322 2.771 (3.414 , 11.331) 6.602 (2.946 , 10.420)
Model 4 562.7 561.9
α0 (intercept) -4.408 0.7133 (-5.806 , -3.010) -3.445 (-4.928 , -2.464)
α1 (age ≥ 50 vs. < 50) -0.586 0.8465 (-2.244 , 1.073) -1.558 (-2.834 , 0.037)
α2 (stage II vs. I) 1.472 0.7731 (-0.043 , 2.987) 0.559 (-0.5678 , 2.039)
α3 (stage III vs. I) 2.152 0.8377 (0.509 , 3.793) 1.142 (-0.1288 , 2.633)
α12 (age vs. stage II) 0.477 1.1565 (-1.789 , 2.744) 1.041 (-1.089 , 2.889)
α13 (age vs. stage III) 0.237 1.0077 (-1.737 , 2.212) 1.123 (-0.5672 , 2.725)
β0 (intercept) -3.028 0.6244 (-4.252 , -1.804) -3.015 (-9.219 , -1.836)
β1 (age ≥ 50 vs. < 50) -8.734 1.8052 (-12.272 , -5.196) -8.243 (-12.19 , -4.538)
β2 (stage II vs. I) -1.186 1.1913 (-3.521 , 1.148) -1.074 (-3.464 , 4.537)
β3 (stage III vs. I) 0.008 0.8434 (-1.644 , 1.661) -0.075 (-2.014 , 5.786)
β12 (age vs. stage II) 10.867 2.1123 (6.727 , 15.008) 9.907 (5.959 , 13.85)
β13 (age vs. stage III) 8.359 1.9524 (4.532 , 12.186) 7.568 (3.585 , 11.62)
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Figure 3: Kaplan–Meier and parametric survival curves of disease-free survival function according to the stage of the disease at
the start of treatment. The parametric curves are based on the Model 2, with parameters estimated by the maximum likelihood
approach. Censored observations are marked by ticks on the survival curves.
patients in clinical stage II, but the age is not an important factor influencing the survival of patients in clinical stage III given that
the survival curves showed in the panel (c) are close to each other.
Models 2, 3 and 4 have similar AIC and DIC values (Table 4), and these values are lower than the respective values calculated
for the Model 1. However, under a clinical point of view, the Model 4 seems to be the most appropriate to the data, given that the
Figure 3 shows the importance of considering the interaction terms for the interpretation of the pattern of association between age,
clinical stages and the time to progression of the disease.
4 Conclusions
Time-to-an-event data including a proportion of individuals who are immune to the event of interest are common, especially in
medical studies. Basic tools for survival analysis usually consider that the survival function S(t) tends to zero as the time t tends
to infinity, and this assumption is unrealistic if immune individuals are present. The use of models based on defective distributions
is a suitable way to analyse data in this situation. In this way, the parametric model based on the modified Gompertz distribution
allows for the estimation of the cure fraction and allows the insertion of a vector of covariates. Moreover, the model can be easily
implemented in computational programs as SAS, R and OpenBUGS, as showed in the Appendix. To illustrate the use of the model
we used a real data set from a cervical cancer study. We can note that the model satisfactorily fitted the data.
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where α12, α13, β12 and β13 are interaction terms. Let us consider the following model formulations:
• Model 1: Model 1 considers only the effect of age (x1). In this case, α2, α3, α12, α13, β2, β3, β12 and β13 are considered
equal to zero.
• Model 2: Model 2 considers only the effect of the stage of the disease (dummy variables x2 and x3). In this case, α1, β1
and the interaction terms α12, α13, β12 and β13, are considered equal to zero.
• Model 3: Model 3 considers the effects of age (x1) and the stage of the disease (x2 and x3) but it does not includes the
interaction terms α12, α13, β12 and β13.
• Model 4: Model 4 considers the effects of age (x1) and the stage of the disease (x2 and x3) and it includes the interaction
terms α12, α13, β12 and β13.
For all regression coefficients, we assumed normal prior distributions with mean 0 and large variance. Both Bayesian and
maximum likelihood estimates are shown in Table 4. The fit of the Models 1 and 2 also considered the estimation of the cure
fraction (η) for each level of the respective independent variable. In the frequentist estimation, standard errors for the cure fraction
were calculated using the Delta method. As an illustration, Figure 3 shows the survival curves estimated by the Kaplan-Meier
method and by the Model 2 using the maximum likelihood approach.
Table 4 shows that the maximum likelihood and the Bayesian estimates are fairly close to each other. Model 1 suggests that
the age do not have a significant effect on the disease-free survival, since the confidence and credible intervals for the parameters
α1 and β1 include the value 0. Model 2 suggests a significant effect of the stage of the disease on the disease-free survival, given
that the confidence and credible intervals for the shape parameters α2 and α3 do not include the zero value (Figure 3).
Although the Model 1 does not evidences a significant effect of the age on the disease-free survival, Model 4 suggest that the
interaction between age and the clinical stages is important to understand the role of the age on the time to progression of the
disease. The confidence and credible intervals for the interaction terms β12 and β13 do not include the zero value, suggesting a
significant effect of interaction. In fact, the survival curves showed in the Figure 4 help us to understand this effect. The parametric
curves in Figure 4 were obtained based on the Model 4, and shown that the age has a strong effect on the disease-free survival of
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Figure 4: Kaplan–Meier and parametric survival curves of disease-free survival function according to the stage of the disease
at the start of treatment and age. The parametric curves are based on the Model 4, with parameters estimated by the maximum
likelihood approach. Censored observations are marked by ticks on the survival curves.
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Appendix
The following R function rMGompertz is used to generate random samples of size n from a modified Gompertz distribution
with parameters α and β.
rMGompertz <- function(n,alpha,beta) {
eta <- exp(-alpha/beta)
m <- rbinom(n,prob=1-eta,size=1)
u <- runif(n,0,1-eta)
y0 <- -(1/beta)*log(1+beta/alpha*log(1-u))
t0 <- ifelse(m,y0,Inf)
maxti <- max(y0*m)
w <- runif(n,0,maxti)
t <- pmin(t0,w)
d <- as.numeric(t0<w)
dados <- data.frame(t,d)
return(dados) }
This is the OpenBUGS code for the Bayesian model based on the modified Gompertz distribution without covariates:
model {
for (i in 1:N) {
S[i] <- exp(-alpha/beta*(1-exp(-beta*t[i])))
h[i] <- alpha*exp(-beta*t[i])
L[i] <- S[i]*pow(h[i],d[i])
logL[i] <- log(L[i])
zeros[i] <- 0
zeros[i] ~ dloglik(logL[i]) }
a ~ dgamma(0.001,0.001)
b ~ dgamma(0.001,0.001)
alpha<-1/a
beta<-1/b
eta<-exp(-(alpha/beta)) }
In this OpenBUGS code, S[i] is the survival function, h[i] is the hazard function, L[i] is the likelihood function, t[i]
is the time to event and d[i] is a censoring indicator.
Under the frequentist approach, the following R code is used to implement the model using the function maxLik of the
maxLik package (Henningsen and Toomet, 2011) for the maximization of the likelihood function.
log.f <- function(parms){
alpha <- parms[1]
beta <- parms[2]
if (parms[1]<0) return(-Inf)
if (parms[2]<0) return(-Inf)
St <- exp(-alpha/beta*(1-exp(-beta*t)))
ht <- alpha*exp(-beta*t)
like <- St * ht^d
L <- sum(log(like))
if (is.na(L)==TRUE) {return(-Inf)}
else {return(L)} }
library(maxLik)
mle <- maxLik(logLik=log.f,start=c(.06,.06))
summary(mle)
Alternatively, SAS users can use the following code:
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data article;
input t d;
cards;
28 0
8 1
116 0
2 1
...
1 1
;;
proc nlmixed data=article df=500;
parms alpha=0.06 beta=0.06;
bounds alpha>0, beta>0;
St = exp(-alpha/beta*(1-exp(-beta*t)));
ht = alpha*exp(-beta*t);
eta = exp(-alpha/beta);
like = St * ht**d;
loglike = log(like);
model t ~ general(loglike);
estimate "eta" eta;
run;
The SAS procedure NLMIXED allows for the fitting of nonlinear and generalized linear models with random effects (Littell et
al., 2006). However, if random effects are not reported in the SAS code, only fixed effects are included in the model. The parms
statement describes the names of parameters and specifies initial values. In order to avoid problems of convergence or a Hessian
matrix with negative eigenvalues, reasonable initial values should be specified for each parameter. An advantage of the use of SAS
procedure NLMIXED is that the estimate statement allows to compute directly the standard error and Wald-type confidence
limits for the parameter η, based on the delta method.
All the computational codes presented here can be readily adapted to situations in which there are multiple independent
variables. For example, under the frequentist approach, the R code for the likelihood function of the Model 4 is the following.
log.f <- function(parms){
alpha0 <- parms[1]
alpha1 <- parms[2]
alpha2 <- parms[3]
alpha3 <- parms[4]
alpha4 <- parms[5]
alpha5 <- parms[6]
beta0 <- parms[7]
beta1 <- parms[8]
beta2 <- parms[9]
beta3 <- parms[10]
beta4 <- parms[11]
beta5 <- parms[12]
alpha <- exp(alpha0 + alpha1*x1 + alpha2*x2
+ alpha3*x3 + alpha4*x1*x2 + alpha5*x1*x3)
beta <- exp(beta0 + beta1*x1 + beta2*x2
+ beta3*x3 + beta4*x1*x2 + beta5*x1*x3)
St <- exp(-alpha/beta*(1-exp(-beta*t)))
ht <- alpha*exp(-beta*t)
like <- St * ht^d
L <- sum(log(like))
if (is.na(L)==TRUE) {return(-Inf)}
else {return(L)} }
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